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Group A streptococcal (GAS) serology is used for the diagnosis of post-streptococcal diseases, such as acute
rheumatic fever, and occasionally for the diagnosis of streptococcal pharyngitis. Experts recommend that the
upper limits of normal for streptococcal serology be determined for individual populations because of differ-
ences in the epidemiology of GAS between populations. Therefore, we performed a study to determine the
values of the upper limit of normal for anti-streptolysin O (ASO) and anti-DNase B (ADB) titers in Fiji.
Participants with a history of GAS disease, including pharyngitis or impetigo, were excluded. A total of 424
serum samples from people of all ages (with a sample enriched for school-aged children) were tested for their
ASO and ADB titers. Reference values, including titers that were 80% of the upper limit of normal, were
obtained by regression analysis by use of a curve-fitting method instead of the traditional nonparametric
approach. Normal values for both the ASO titer and the ADB titer rose sharply during early childhood and
then declined gradually with age. The estimated titers that were 80% of the upper limit or normal at age 10
years were 276 IU/ml for ASO and 499 IU/ml for ADB. Data from our study are similar to those found in
countries with temperate climates, suggesting that a uniform upper limit of normal for streptococcal serology
may be able to be applied globally.
Streptococcal antibody tests are used for the diagnosis of
antecedent infections caused by the group A streptococcus
(GAS) and are particularly useful for the diagnosis of acute
rheumatic fever and acute post-streptococcal glomerulone-
phritis. Acute rheumatic fever is an autoimmune disease that
follows infection with GAS; however, the isolation of GAS is
uncommon (15%), and so confirmation of the diagnosis of-
ten relies on streptococcal antibody tests (13). While a number
of tests utilize different antigens of GAS, the most frequently
performed tests are those that determine the anti-streptolysin
O (ASO) titer and the anti-DNase B (ADB) titer (8, 18).
Ideally, it is recommended that the titer be determined in the
acute phase and then determined in the convalescent phase 14
to 28 days later, with a positive result defined as a rise in titer
of twofold or more (26). However, it is not always practicable
to obtain a second sample for titer determination, particularly
in developing countries, where acute rheumatic fever is the
most common. Therefore, it is generally accepted that if only a
single specimen is available, a titer greater than the upper limit
of normal at the initial testing can be considered presumptive
evidence of a preceding streptococcal infection (10, 12, 26).
The upper limit of normal for streptococcal serology has
been defined by separating the upper 20% from the lower 80%
of the group distribution in a dichotomous fashion (4, 12, 26).
The choice of the 80th centile cutoff rather than more tradi-
tional upper-limit-of-normal calculations (e.g., 2 standard de-
viations from the mean) is based upon studies that found that
more than 80 to 90% of patients with acute rheumatic fever or
post-streptococcal glomerulonephritis have streptococcal titers
that are above the 80th centile for the healthy controls with no
clinical evidence of recent streptococcal infection (4, 26).
Therefore, it is assumed that in any population a proportion of
apparently healthy individuals will have had a recent, subclin-
ical GAS infection (4).
Streptococcal titers vary according to a number of factors,
including age and population. In developed countries, where
impetigo caused by GAS is uncommon, streptococcal titers in
the population primarily reflect the incidence of pharyngeal
infection with GAS; therefore, the titers in healthy people are
low in early childhood, rise to a peak in children aged 5 to 15
years, decrease in late adolescence and early adulthood, and
then flatten off after that (9, 12). In contrast, in populations
with high rates of impetigo, background antistreptococcal ti-
ters are often very high, especially in children, probably be-
cause most children tested have had a recent streptococcal
infection (15, 25).
Because of these differences in titers with age, it is recom-
mended that age-stratified upper-limit-of-normal values be de-
termined for populations of interest by testing people who
have not had a recent streptococcal infection (12). Age-strat-
ified upper-limit-of-normal reference values have been defined
for the U.S. pediatric population, the Australian pediatric pop-
ulation, and the Indian pediatric population, among others (5,
7, 9, 11, 17). However, there has been no investigation of
upper-limit-of-normal values for populations in the Pacific re-
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gion, where some of the highest rates of acute rheumatic fever
and acute post-streptococcal glomerulonephritis are known to
occur and where impetigo is common in children (6, 21, 24).
For studies that determine streptococcal serology reference
ranges, it is important that a representative group of individ-
uals without a known recent streptococcal infection be sam-
pled (12). The immune response to GAS infections should be
considered in determining which subjects should be excluded
from analysis (18). The ASO titer tends to rise a week follow-
ing infection, peaks at 3 to 5 weeks, and begins to decline after
8 weeks; and it responds more vigorously to pharyngeal infec-
tion than skin infection. The ADB titer peaks at 6 to 8 weeks
after infection and begins to decline at 12 weeks, and it re-
sponds vigorously to both pharyngeal and skin infections.
Therefore, subjects with recent pharyngitis or skin infections
should not be included in the sample. The exclusion of children
with GAS throat carriage is not necessary, as all healthy pedi-
atric populations include carriers of GAS (9).
A variety of statistical techniques for constructing age-spe-
cific reference values are available (27). Previous comparable
studies investigating reference values for streptococcal serol-
ogy have used nonparametric calculations by pooling data by
age group and calculating an 80th centile cutoff value for each
of the age groups (7, 9). However, more robust and efficient
statistical methods that take advantage of parametric regres-
sion modeling techniques are available for the analysis of age-
specific reference values (16).
In this study, we document for the first time the normal
ranges of the ASO and ADB titers in all age groups in a Pacific
island country and also present an alternative method for an-
alyzing these data.
MATERIALS AND METHODS
Setting. Fiji is a nation of approximately 330 islands located in the western
Pacific. It has a population of 827,900 people comprising two major racial groups:
indigenous Fijians (57.3%) and Indo-Fijians (37.6%) (3). Fiji is ranked 90 of 177
nations on the United Nations Development Programme’s Human Development
Index. It has a per capita gross domestic product of $6,066 and an infant
mortality rate of 16.8 per 1,000 population (1, 2). Approximately 49% of the
population lives in rural areas (3). The major hospital, the Colonial War Me-
morial Hospital, is located in the capital, Suva, on the main island of Viti Levu
and predominantly serves the largest region of Fiji, the Central Division. GAS
disease is common in Fiji, with high rates of invasive GAS disease, acute rheu-
matic fever, and rheumatic heart disease (14, 19, 22). In addition, there is a high
prevalence (over 35%) of impetigo among schoolchildren (20), and the incidence
of GAS culture-positive sore throat is similar to that in developed countries
(approximately 15 cases per 100 child years) (23).
Sample. Blood was collected from participant groups enrolled in two different
studies. The first group comprised 280 volunteers of all ages identified through
the Colonial War Memorial Hospital. The enrollment was designed so that there
was an even distribution of participants from birth to age 65 years. All of these
280 participants were prospectively screened for current or recent GAS infection.
We excluded any participant from enrollment by direct inquiry of the participant
and by checking their medical records for the following: a history of acute
rheumatic fever, rheumatic heart disease, or invasive GAS disease and a history
in the previous 14 days of sore throat or skin sores. We also excluded participants
who had a temperature of 38.0°C on the day of enrollment.
In order to enrich the sample for children in the age group that has been found
in other studies to have the highest background antistreptococcal antibody titers,
we included a second group of 423 schoolchildren aged 4 to 14 years enrolled as
part of a separate prospective cohort study designed to study GAS pharyngitis
and GAS impetigo. This study was conducted in three primary schools in the
Central Division of Fiji. Two schools were located in a rural area, while a third
school was located in Fiji’s capital city, Suva. The participants in these schools
were screened retrospectively for potential GAS disease. We excluded children
with any of the following: rheumatic heart disease proven on echocardiogram
(because these children are at a higher risk of acute rheumatic fever at any time);
recent GAS pharyngitis; and any evidence of impetigo, which included dry,
crusted, or pustular lesions.
Collection, transport, and testing of specimens. Blood specimens were taken
and immediately stored in a cool box. The samples were transported to the
laboratory on the same day, and on arrival at the laboratory, the samples were
centrifuged and the serum was divided into three aliquots and stored at 70°C.
One aliquot was thawed and tested for ADB in our Fiji laboratory. Another
aliquot was transported to Queensland, Australia, where it was thawed and
tested for ASO titer.
ASO titers were measured by a nephelometric technique (Beckman Coulter,
Fullerton, CA), as described previously (2). ADB titers were measured by an
enzyme inhibition assay (bioMerieux, Marcy l’Etoile, France), as described pre-
viously (2). Both methods provide an inexact figure for low titers (titers of 60
IU/ml for ASO and titers of 100 IU/ml for ADB); for these values, we esti-
mated midtiter values (a titer of 30 IU/ml for ASO and a titer of 50 IU/ml for
ADB).
Statistical methods. We followed a previously described technique for con-
structing age-specific reference ranges (16). The raw data for both ASO and
ADB titers were logarithmically transformed from a positively skewed distribu-
tion to a normal distribution. A regression analysis of the log values was per-
formed by using fractional polynomials to handle nonlinearity. With this method,
we created smoothed fitted curves against age. From the fitted curves, we ob-
tained median and 80% upper-limit-of-normal values for five age groups from
age 1 year to 65 years and also by year of age for children aged 5 to 14 years. Data
were analyzed by using the Stata (version 10.0) program (Stata-Corp, College
Station, TX).
Ethical approval. Ethical approval was obtained from the Fiji National Re-
search Ethics Review Committee, the Fiji National Health Research Committee,
the University of Melbourne Human Research Ethics Committee, and the
Queensland Institute of Medical Research Human Research Ethics Committee.
We approached all participants for their consent, and prior to enrollment infor-
mation sheets in Fijian and English were provided. We required that all partic-
ipants provide written informed consent before information was collected. Chil-
dren were enrolled only if written consent was obtained from a parent or
guardian, and we also insisted on written assent by children aged 10 years or
older.
RESULTS
Sample. All samples from the 280 participants in the first
study group were included in the analysis. Of this group, there
were 26 participants who were inpatients for non-GAS disease,
87 blood donors, and 167 outpatients. Among the 423 partic-
ipants in the second group, 3 participants with rheumatic heart
disease were excluded from the analysis, there were no chil-
dren with a history of GAS pharyngitis in the preceding 14
days, and 273 children with evidence of impetigo were ex-
cluded from the analysis. When the data were log transformed,
it was noted that there were three extreme outliers (one par-
ticipant with an ASO titer of 1,999 and two participants with
ADB titers of 2,999), and these values were excluded from
the analysis. Therefore, a total of 424 blood samples were
included in the study. Table 1 summarizes the demographic
features of the study participants.
ASO and ADB titer analysis. There was a peak in the mean
titers of both ASO and ADB in the 5- to 14-year-old age group,
with a gradual decrease occurring following this peak (Fig. 1).
The estimated median and 80% upper-limit-of-normal values
for five age groups are presented in Table 2. There are no
values presented in Table 2 for children aged less than 1 year
because of the small number of values and the steep incline of
the curve. Table 3 presents these data in more detail for chil-
dren aged 5 to 14 years.
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DISCUSSION
We found the normal values for streptococcal serology to be
similar to those that have been reported from other regions. In
comparison to data from the United States and from Australia,
we found that the overall values for the ASO titers were only
slightly lower in our study and that the values for the ADB
titers were only slightly higher (8, 9). The slightly higher ADB
titers are probably due to the fact that impetigo is endemic in
Fiji, particularly in children (20). Although we excluded chil-
dren with a recent history of impetigo, the ADB titers remain
elevated for many months; hence, we are likely to have in-
cluded some children whose ADB titers were in the process of
returning to their baseline level after a case of impetigo.
Although some have claimed that normal ranges for strep-
tococcal antibody titers are higher in populations with endemic
streptococcal infections, this is incorrect. The studies on which
these statements were based did not meticulously exclude chil-
dren with recent streptococcal infections. For example, a study
with an aboriginal community in Australia, in which impetigo
was very common among the children of the community, found
median titers of 256 IU/ml and 3,172 IU/ml for ASO and ADB,
respectively, but did not exclude children with current or re-
cent impetigo (15). The very close similarities of the titers
between our study in a tropical country and studies in temper-
ate zones provide evidence and impetus for the notion that
single upper-limit-of-normal values for ASO and ADB titers
may be able to be applied globally. Similar data from India
support this notion (11,12).
By applying the simple nonparametric technique that has
TABLE 1. Demographic details of study participantsa
Characteristic No. (%) of subjects
Age (yr)
5....................................................................................... 44 (10.4)
5–14 ....................................................................................186 (43.8)
14.....................................................................................194 (45.8)
Gender
Female ...............................................................................202 (47.6)
Male ...................................................................................222 (52.4)
Ethnicity
Indigenous Fijian ..............................................................230 (54.3)
Indo-Fijian.........................................................................164 (38.7)
Other .................................................................................. 30 (7.0)
a The data are for 424 participants.
FIG. 1. ASO titer (A) and ADB titer (B) versus age. The solid line
represents the 80th centile (upper limit of normal), the dashed line
represents the geometric mean (equivalent to the median) titer, and
the dotted lines represent the 2.5th and the 97.5th centiles.
TABLE 2. Median and 80% upper-limit-of-normal reference values
for ASO titer and ADB titer, by age groupa
Age (yr) No. ofsubjects
ASO titer (IU/ml) ADB titer (IU/ml)
Median
80% upper
limit of
normal
Median
80% upper
limit of
normal
1–4 18 89 170 185 366
5–14 186 145 276 257 499
15–24 50 126 238 249 473
25–34 51 95 177 211 390
35 93 69 127 148 265
a The data were derived from the fractional polynomial regression model for
log titer.
TABLE 3. Median and 80% upper-limit-of-normal reference values
for ASO and ADB titers, by yearly age group for children aged
5 to 14 years
Age (yr) No. ofsubjects
ASO titer (IU/ml) ADB titer (IU/ml)
Median
80% upper
limit of
normal
Median
80% upper
limit of
normal
5 16 116 222 220 433
6 13 126 241 232 455
7 17 134 255 241 472
8 24 139 265 248 484
9 27 143 272 253 493
10a 27 145 276 257 499
11 22 146 278 259 503
12 32 146 277 261 504
13 6 145 275 261 504
14 2 144 272 261 503
a The data were derived as described in footnote a of Table 2. Note that the
reference values for the 5- to 14-year-old age group in Table 2 are the reference
values estimated for age 10.
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been used in previous studies to analyze our data, we found
cutoff values similar to those obtained by the parametric
method. However, the parametric method of data analysis that
we used in this study has some advantages over the nonpara-
metric method. The nonparametric method often produces
implausible irregular patterns in the centiles with age, unless a
large sample is used and wide age intervals are specified. The
results may be artificially affected by the choice of age groups,
especially when titers have a complex pattern of change with
age. In comparison, the curve-fitting method produces smooth
centile curves (that is, the reference value varies smoothly with
age), and it allows both the level and the spread of the refer-
ence distribution to change with time.
We will recommend that Fijian clinicians use a single upper-
limit-of-normal cutoff value for children aged 5 to 14 years
(that is, the estimated 80% upper-limit values at 10 years,
which were 276 IU/ml for the ASO titer and 499 IU/ml for the
ADB titer; Table 2) rather than the cutoff values for sub-
groups, such as 4 to 5 years, 6 to 9 years, and 10 to 14 years, as
recommended in other studies. This is because only minimal
variability in the year-by-year values was found for children
aged 5 to 14 years (Table 3). The use of a single cutoff value for
this age group also makes it far simpler for laboratory staff to
report results and for clinicians to interpret them (12).
This study provides upper-limit-of-normal values for strep-
tococcal serology for people of all ages in Fiji determined by
using a robust and readily repeatable parametric statistical
technique. These upper-limit-of-normal values will guide clini-
cians in Fiji when they consider the diagnosis of post-strepto-
coccal diseases in their patients and will provide useful baseline
data for future studies of interventions against GAS disease in
Fiji. Our data could also be applied to surrounding Pacific
island countries.
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